582 related articles for article (PubMed ID: 30504040)
1. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).
Fragoso YD; Sousa NAC; Alves-Leon SV; Dias RM; Pimentel MLV; Gomes S; Goncalves MVM; Stella CV; Tauil CB; Anacleto A; Spessotto CV; Correa EC; Eboni ACB; Damasceno A; Damasceno B; Farinhas JGD; Mota RSS; Nogueira EGA; Pereira VCSR; Scorcine C; Bacon T; Kister I
Mult Scler Relat Disord; 2019 Jan; 27():392-396. PubMed ID: 30504040
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
6. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
9. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
10. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
12. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
Ungureanu A; de Seze J; Ahle G; Sellal F
Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset.
Fragoso YD; Sousa NAC; Saad T; Alves-Leon SV; Pimentel MLV; Goncalves MVM; Stella CV; Diniz DS; Santos GC; Gomes S; Adoni T; Anacleto A; Claudino R; Malfetano FR; Winckler TCD; Damasceno A; Eboni ACB; Farinhas JGD; Mota RSS
J Child Neurol; 2019 Aug; 34(9):487-490. PubMed ID: 31012355
[TBL] [Abstract][Full Text] [Related]
14. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
15. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
[TBL] [Abstract][Full Text] [Related]
16. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
19. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
de Seze J
Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
[TBL] [Abstract][Full Text] [Related]
20. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]